Harari, Daniel <br/><br/>
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.  [electronic resource] 

 -  Human molecular genetics  Jun 2015 
 - 3192-205 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1460-2083 
<br/><br/><label>Standard No.: </label>10.1093/hmg/ddv071  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--pharmacology<br/>Humans<br/>Interferon beta-1a--pharmacology<br/>Interferon beta-1b--pharmacology<br/>Multiple Sclerosis--blood<br/>Transcriptome--drug effects